Loading
A phase 3 trial of Fulzerasib, Garsorasib and Glecirasib in Non-small-cell lung cancer, run by Shandong Suncadia Medicine Co., Ltd., not yet recruiting.
A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment is a phase 3 interventional study registered as NCT07601048 by Shandong Suncadia Medicine Co., Ltd., with 450 participants planned, started 2026-06 and due to reach its primary completion in 2028-05. Interventions recorded: HRS-7058, Fulzerasib Tablets, Garsorasib Tablets, Glecirasib Citrate Tablets. Conditions recorded: KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment.
Linked to the drug Fulzerasib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fulzerasib, KRAS G12C-mutant non-small-cell lung cancer and the tag pipeline.
Shares Glecirasib, KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Non-small-cell lung cancer and the tag pipeline.
Shares Garsorasib, KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Fulzerasib and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Garsorasib and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/